ArticleAsia Pacific allergy2021
Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma.
Article in Asia Pacific allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Galectin-10 and Charcot-Leyden Crystals in Chronic Rhinosinusitis with Nasal Polyps: Pathogenetic Insights and Clinical Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Associations Between Different Eosinophil Activity Markers and Clinical Outcomes in Young Asthmatics.Clinical and translational allergy · 2026Article
- Severe Chronic Rhinosinusitis with Nasal Polyps: From IL-5-Driven Pathogenetic Mechanisms to Clinical Management in the Italian Clinical Setting.Journal of inflammation research · 2026Review
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- Precision Medicine in Asthma: The Role of Biomarkers.ImmunoTargets and therapy · 2025Review
- Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.Frontiers in immunology · 2025Article
- The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review.Current issues in molecular biology · 2024Review
- Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.Life (Basel, Switzerland) · 2023Article
- Lactose and Galactose Promote the Crystallization of Human Galectin-10.Molecules (Basel, Switzerland) · 2023Article
- Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review.Antioxidants (Basel, Switzerland) · 2023Review
- Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Frontiers in medicine · 2023Review
- Galectin-10 as a Potential Biomarker for Eosinophilic Diseases.Biomolecules · 2022Review
- Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma.ERJ open research · 2022Article
- Preface of the Proceedings of the 34rd Workshop on Eosinophils in Allergy and Related Diseases 2020 (WEA 2020).Asia Pacific allergy · 2021Article
- Glimpses of the life journey of Prof. Sohei Makino, MD, PhD.Asia Pacific allergy · 2021Article
- Long Term Effectiveness of Mepolizumab in the Treatment of Chronic Eosinophilic Pneumonia.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMepolizumab, a humanized antibody targeting interleukin-5, decreases the number of blood eosinophils and the frequency of exacerbation of severe asthma. Galectin-10 is a protein within the cytoplasm of eosinophils and constitutes Charcot-Leyden crystals, which promotes key features of asthma. However, the relationship between time kinetics and clinical response of eosinophil-derived molecules such as galectin-10 or eosinophil cationic protein (ECP) has not been precisely investigated.
objectiveThis study aimed to clarify the precise time course of the levels of serum galectin-10 and ECP after mepolizumab treatment and to analyze the relationship between the levels of eosinophil-derived molecules and the clinical background or response to mepolizumab treatment.
methodsThis multicenter, prospective open-label study recruited 20 patients with severe eosinophilic asthma. Mepolizumab was administered every 4 weeks for 32 weeks and the levels of various biomarkers were serially analyzed.
resultsThe serum galectin-10 and ECP significantly and rapidly decreased 4 weeks after initial administration of mepolizumab. In contrast, basophil count, fractional exhaled nitric oxide, and the serum total IgE level were unchanged during treatment. Asthma Control Questionnaire-5, Asthma Health Questionnaire-33, and Lund-Mackay scores significantly improved after mepolizumab treatment. Both high ECP and eosinophil count related to better response in forced expiratory volume in 1 second (FEV
conclusionThis study was the first to show that the levels of serum galectin-10 decreases after initial administration of mepolizumab. The significant relationship between serum ECP and better response in FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.